Based on clinical and molecular evidence, two progression pathways have been described in bladder cancer, the Ta pathway presenting high frequency of FGFR3 mutation and the Cis pathway with no or low rate of FGFR3 mutation. Here, FGFR3 is linked to urinary bladder carcinoma.